Answers are grounded in this paper and cite their sources.
Inflammation is a primary immune response categorized into acute and chronic types, with chronic inflammation linked to various diseases such as autoimmune disorders and cancer. Conventional therapies often face limitations due to side effects and therapeutic resistance, prompting the exploration of small-molecule compounds as safer alternatives. In this study we emphasize the integration of machine learning (ML), particularly through structure-activity relationship (SAR) analysis and quantitative structure-activity relationship (QSAR) modeling, to enhance drug discovery. A series of ML-based regression models, including LightGBM, were developed and systematically evaluated. Various feature selection method, were employed to effectively reduce the input dimensionality and improve model performance. The LightGBM model, based on combined Morgan and substructure count fingerprints, achieved strong predictive performance with an R² of 0.75 on the independent test dataset. External validation with FDA-approved compounds affirmed the model's applicability, highlighting key structural features identified through explainable artificial intelligence (XAI) techniques, specifically SHAP and LIME. This study concludes that the AISM-REGBF framework provides a reliable computational tool for predicting the anti-inflammatory potency (pIC₅₀) of small molecules.
No takes yet. Share an insight, caveat, or question.
Selvam et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: